🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Global Challenge

The sexually transmitted infection are escalating around the world, with data suggesting more than 82 million new cases per year. Especially elevated rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Clearance

Zoliflodacin, also known as a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This authorization marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

Based on results released by a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The research enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in many regions with limited resources.

Medical professionals directly involved have voiced optimism. The availability of a easy-to-administer therapy like this is seen as a "revolutionary step" for gonorrhoea control. This is deemed vital to reduce the burden of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.